Hume Kyle - Sumitomo Dainippon Insider

DPM -- Germany Stock  

EUR 18.58  0.26  1.42%

CFO, Executive Vice President
Mr. Hume D. Kyle is a Chief Financial Officer and Executive Vice President of Dundee Precious Metals Inc., with effective from June 6, 2011. Mr. Kyle has more than 25 years of experience as a financial executive in a number of complex, publicly traded, multinational energy and natural resource businesses. He has held a range of increasingly senior roles in public practice and private industry including Assistant Treasurer, Treasurer Vice President, Finance and Controller, and Chief Financial Officer. Most recently, Mr. Kyle served as Vice President, Treasurer and Controller, of TransAlta Corporationrationration, an 11 billion power generating company where he was responsible for providing leadership over the financial activities of the organization, principally in the areas of corporate accounting and reporting, strategic finance, treasury, taxation, and financial systems, processes and controls
  President Since 2011      
81 6 6203 5321  http://www.ds-pharma.com
Kyle holds a Bachelor of Arts degree in Economics and Accounting from the University of Western Ontario and a Graduate Diploma in Public Accounting from McGill University. He is also a Chartered Accountant and a Chartered Financial Analyst.

Management Efficiency

The company has return on total asset (ROA) of 6.45 % which means that it generated profit of $6.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.7 % meaning that it generated $11.7 on every $100 dollars invested by stockholders.
The company has accumulated 450.43 M in total debt with debt to equity ratio (D/E) of 10.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sumitomo Dainippon Pharma Co Ltd has Current Ratio of 1.63 which is within standard range for the sector.

Similar Executives

Entity Summary

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited. Sumitomo Dainippon operates under Drug Manufacturers - Specialty Generic classification in Germany and traded on Frankfurt Stock Exchange. It employs 6268 people.Sumitomo Dainippon Pharma Co Ltd (DPM) is traded on Frankfurt Stock Exchange in Germany. It is located in 6-8 Doshomachi 2-chome and employs 6,268 people.

Sumitomo Dainippon P Leadership Team

Peter Nixon, Director
Jonathan Goodman, CEO, MBA
Richard Gosse, President
Colin McAnuff, Executive
John Lindsay, President
Mark Crawley, President
Peter Gillin, Director
MarieAnne Tawil, Director, MBA
Richard Howes, President
Hume Kyle, President
Anthony Walsh, Director
Garth MacRae, Director
Zebra Kasete, President, MBA
Juanita Montalvo, Director
David Rae, President
Donald Young, Director
Michael Dorfman, President
Lori Beak, President
Jeremy Kinsman, Director, MBA
Brent Johnson, President
Paul Proulx, President
Nikolay Hristov, President
Murray John, Director, MBA
Hratch Jabrayan, President

Stock Performance Indicators

Current Sentiment - DPM

Sumitomo Dainippon P Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Sumitomo Dainippon Pharma Co Ltd. What is your outlook on investing in Sumitomo Dainippon Pharma Co Ltd? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Sumitomo Dainippon and Alphabet. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.